Cardiff Oncology
CRDF
87 hedge funds and large institutions have $132M invested in Cardiff Oncology in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 21 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.92% less ownership
Funds ownership: 53.41% → 52.48% (-0.92%)
4% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 26
6% less capital invested
Capital invested by funds: $141M → $132M (-$8.62M)
7% less funds holding
Funds holding: 94 → 87 (-7)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
34% less call options, than puts
Call options by funds: $895K | Put options by funds: $1.36M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.99M |
| 2 |
Morgan Stanley
New York
|
+$2.64M |
| 3 |
Millennium Management
New York
|
+$1.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$870K |
| 5 |
BlackRock
New York
|
+$861K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.25M |
| 2 |
Two Sigma Investments
New York
|
-$1.36M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$400K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$292K |
| 5 |
Two Sigma Advisers
New York
|
-$213K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Rockefeller Capital Management
New York
| – | +$36 | +6 | New |
|
CRDF Hedge Fund Activity: Q4 2021 in Review
87 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2021, worth a combined $132M — down 6.1% from $141M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CRDF and 14 opened new positions — a net loss of 7 holders — while 26 trimmed existing stakes and 25 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.99M. The largest seller was Citadel Advisors, cutting an estimated $4.25M.
- 87 institutional investors held Cardiff Oncology (CRDF) as of Q4 2021, down from 94 in Q3 2021.
- Funds reported $132M of Cardiff Oncology stock for Q4 2021, down 6.1% quarter-over-quarter.
- 14 funds opened new Cardiff Oncology positions in Q4 2021 and 21 closed out, a net change of -7 holders.
- The largest Cardiff Oncology buyer in Q4 2021 was Point72 Asset Management, an estimated $2.99M added.
- The largest Cardiff Oncology seller in Q4 2021 was Citadel Advisors, an estimated $4.25M sold.
Based on aggregated 13F filings for Q4 2021.